Publications by authors named "M R DeGuzman"
Efficacy and Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis-A Double-Blind Placebo Controlled Clinical Trial (The Pediatric Lupus Nephritis Mycophenolate Mofetil Study).
J Clin Trials
May 2024
Background: The safety and efficacy of mycophenolate mofetil (MMF) for lupus nephritis (LN) treatment is established in adults and in some children. MMF is rapidly converted to the biologically active metabolite mycophenolic acid (MPA) whose pharmacokinetics (PK) is characterized by large inter- and intra-individual variability.
Methods/design: This randomized, double-blind, active comparator, controlled clinical trial of pediatric subjects with proliferative LN compares pharmacokinetically-guided precision-dosing of MMF (MMF, i.
Background: A better understanding of the pathogenesis of polyarticular juvenile idiopathic arthritis (polyJIA) is needed to aide in the development of data-driven approaches to guide selection between therapeutic options. One inflammatory pathway of interest is JAK-STAT signaling. STAT3 is a transcription factor critical to the differentiation of inflammatory T helper 17 cells (Th17s).
View Article and Find Full Text PDFJuvenile eosinophilic fasciitis: a single center case series.
Pediatr Rheumatol Online J
February 2024
Article Synopsis
- Eosinophilic fasciitis (EF) is a rare condition affecting the skin and muscles, but there’s limited research on how it presents in children compared to adults.
- A study reviewed six pediatric cases of EF, identifying symptoms like painful swelling and joint limitations, with most patients being female and diagnosed between ages 4 and 16.
- Treatment varied but included corticosteroids and other immunosuppressive drugs; unlike adults, no malignancies or trauma were found in these children, and a specific sign called the "prayer sign" may help early diagnosis.
Purpose: To characterize and analytically validate the MSDA Test, a multi-protein, serum-based biomarker assay developed using Olink PEA methodology.
Experimental Design: Two lots of the MSDA Test panel were manufactured and subjected to a comprehensive analytical characterization and validation protocol to detect biomarkers present in the serum of patients with multiple sclerosis (MS). Biomarker concentrations were incorporated into a final algorithm used for calculating four Disease Pathway scores (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity) and an overall Disease Activity score.